Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / BMY - Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy


BMY - Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

2024-02-01 12:36:15 ET

Summary

  • Century Therapeutics is a biotech focused on developing engineered natural killer cells for cancer and rheumatologic conditions.
  • Their first clinical product, CNTY-101, showed promising early data with a patient experiencing tumor shrinkage and a complete clinical response.
  • However, Century Therapeutics has a limited cash position and needs to prove the efficacy of their therapies before being considered a confident investment.

Topline Summary

For further details see:

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy
Stock Information

Company Name: Bristol-Myers Squibb Company
Stock Symbol: BMY
Market: NYSE
Website: bms.com

Menu

BMY BMY Quote BMY Short BMY News BMY Articles BMY Message Board
Get BMY Alerts

News, Short Squeeze, Breakout and More Instantly...